PurMinds NeuroPharma Names New Chief Business Officer

PurMinds NeuroPharma, a clinical-stage neuroscience company focused on advancing a pipeline of small molecules, psychedelic compounds, and other modalities for the treatment of neurological and neurodegenerative disorders, has named Vanessa Williamson as Chief Business Officer, effective May 20, 2024.
 
“We are thrilled to welcome Vanessa to the PurMinds leadership team during this pivotal stage of our growth,” said Janet Qi, CPA. MBA. Co-Founder & CEO of PurMinds NeuroPharma. “Her impressive track record in forging strategic alliances, fundraising success, and fostering innovation ecosystems will be invaluable as we accelerate the development of our breakthrough therapies and explore new avenues for value creation.”
 
Prior to joining PurMinds, Williamson held executive roles at companies such as SQI Diagnostics Systems, Inc., Precision BioMonitoring, Inc., and the Ontario Centres of Excellence, among others. She has a proven ability to identify and execute upon unexpected opportunities, establishing win-win partnerships and strategic alliances that drive corporate growth and exceed stakeholder expectations.
 
“I am excited to join the pioneering team at PurMinds and contribute my expertise to advance their groundbreaking work in neuroscience,” said Williamson. “PurMinds’ innovative approach to developing novel therapies for neurological and neurodegenerative disorders has the potential to transform lives and I look forward to supporting the company’s mission through strategic collaborations and partnerships.”